Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.93 USD
+0.05 (2.66%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $1.91 -0.02 (-1.04%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.93 USD
+0.05 (2.66%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $1.91 -0.02 (-1.04%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $9.18, moving -1.71% from the previous trading session.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
by Zacks Equity Research
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -0.78% move from the previous day.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.
Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Actinium Pharmaceuticals, Inc. (ATNM).
Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Actinium Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ATNM) Outperforming Other Medical Stocks This Year?
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval
by Zacks Equity Research
FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.
Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Actinium Pharmaceuticals (ATNM) stock based on the movements in the options market lately.
How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.